Related references
Note: Only part of the references are listed.2011 Recommendations for the Diagnosis and Management of Gout and Hyperuricemia
Max Hamburger et al.
POSTGRADUATE MEDICINE (2012)
Prevalence of Gout and Hyperuricemia in the US General Population The National Health and Nutrition Examination Survey 2007-2008
Yanyan Zhu et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Pegloticase
Naomi Schlesinger et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
CME MULTIMEDIA ACTIVITY Managing Gout in the Primary Care Setting: What You and Your Patients Need to Know
Paul P. Doghramji et al.
AMERICAN JOURNAL OF MEDICINE (2010)
Chronic gout: epidemiology, disease progression, treatment and disease burden
Richard A. Brook et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout
Michael A. Becker et al.
JOURNAL OF RHEUMATOLOGY (2009)
PEG-uricase in the management Of treatment-resistant gout and hyperuricemia
Merry R. Sherman et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
Treatment-failure gout: A moving target
N. Lawrence Edwards
ARTHRITIS AND RHEUMATISM (2008)
Lowering serum uric acid levels:: What is the optimal target for improving clinical outcomes in gout?
Fernando Perez-Ruiz et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout
Eliseo Pascual et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout
Kelsey M. Jordan et al.
RHEUMATOLOGY (2007)
Open-label extension studies - Do they provide meaningful information on the safety of new drugs?
Richard O. Day et al.
DRUG SAFETY (2007)
EULAR evidence based recommendations for gout.: Part II:: Management.: Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT)
W. Zhang et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy
A Shoji et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2004)
Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout
F Perez-Ruiz et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2002)
Share Paper
